Close Menu

NEW YORK – Biocept said after the close of the market on Wednesday that its fourth quarter revenues more than doubled year over year, driven by 46 percent growth in commercial test volume and 34 percent growth in average insurance reimbursement per patient.

For the three months ended Dec. 31, 2019, the San Diego-based liquid biopsy test provider tallied $1.8 million in total revenues compared to $859,526 in the year-ago period.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.